1.TUNE and TWEAK my diet, Nothing too strange, lower and better fats, almost no red meat, fresh and organic vegies, etc. Started this at the begining. Also avoid all chemicals, solvents, cleaners etc. (not easy in my line of work)
2. Start an exercise regimen, mostly biking and hiking. Best shape I've been in in years and years.(BMI was alredy ok)
3. I started pre-dosing Alinia 7/7/08 ------
4-week Lead-in
In a related poster, the investigators presented results from a study in which the lead-in nitazoxanide monotherapy phase was shortened to 4 rather 12 weeks.
In this study, 44 treatment-naive Egyptian patients (40 with genotype 4; 3 with genotype 1; 1 with genotype 2) received 500 mg twice-daily nitazoxanide for 4 weeks followed by nitazoxanide plus 180 mcg/week pegylated interferon for 36 weeks, without ribavirin. Sustained response rates at 12 weeks (SVR12) were reported.
Results
• 80% of patients treated with the 4-week lead-in dual therapy regimen achieved SVR12, compared with 50% in the standard-of-care arm of STEALTH C-1 (used as a historical control) (P = 0.004).
• RVR, EVR, and ETR rates for the 4-week lead-in, as well as the 12-week lead-in in STEALTH C-1, are shown in the table below.
• All the genotype 1 and 2 patients responded to the 4-week lead-in regimen.
• Adverse events were similar to those observed in STEALTH C-1.
• There were no serious adverse events or discontinuations due to adverse events.

The investigators concluded that, "The nitazoxanide lead-in phase used in the STEALTH C-1 trial can be reduced from 12 weeks to 4 weeks without compromising RVR, EVR, and ETR rates."
The results from these 2 studies "confirm earlier data suggesting synergistic activity between nitazoxanide and peginterferon in genotype 4 patients and provide a first look at sustained virologic response in a limited number of genotype 1 patients," Rossignol said in a press release issued by Romark. "These data also provide interesting insights into the mechanism of action of nitazoxanide and confirm previous findings related to its safety."
The second study, he added, "show that the nitazoxanide lead-in phase prior to standard of care treatment can be reduced from 12 to 4 weeks with no apparent impact on virologic response rates." (More Alinia info-
http://www.medhelp.org/user_journals/show/2391 ) I have experience almost no sx from Alinia.
4. 800mg E, 1000mg C daily to help with anemia as per Dr. E.R. Shiffs' Tx Reporter ( I found this report to be very helpful and have given copies to my family so they might be more prepared for what may come) http://www.projectsinknowledge.com/Init/G/1603/order.html
5. 2700 mg daily PPC ---PubMed study at: http://tinyurl.com/6jmsey
PROLONGED PPC THERAPY GIVEN TO RESPONDERS BEYOND THE CESSATION
OF INTERFERON THERAPY TENDED TO INCREASE THE RATE OF SUSTAINED RESPONDERS AT WEEK
48 IN PATIENTS WITH HEPATITIS C (41% VERSUS 15% IN THE CONTROL GROUP; p = 0.064).
BACKGROUND/AIMS: Polyunsaturated phospatidyl-choline (PPC) has been shown to
reduce serum aminotransferases in experimental hepatitis. This multi-center,
randomized, double-blind, placebo-controlled trial evaluated the effects of PPC
in patients with chronic hepatitis B and C in combination with interferon alpha
2a or 2b. The diagnosis of chronic viral hepatitis was based on an abnormal serum
alanine aminotransferase (ALT) value (more than twice the upper value of normal),
viral replication and chronic hepatitis found on liver biopsy. METHODOLOGY:
Patients received 5 million I.U. (Hepatitis B) and 3 million I.U. (hepatitis C)
interferon s.c. thrice weekly for 24 weeks, respectively, and were randomly
assigned to additional oral medication with either 6 capsules of PPC (total daily
dose: 1.8 g) or 6 capsules of placebo per day for 24 weeks. Biochemical response
to therapy was defined as a reduction of ALT by more than 50% of pre-treatment
values. The responders were treated for further 24 weeks after cessation of
interferon therapy with either PPC or placebo. RESULTS: 176 patients completed
the study protocol (per-protocol population: 92 in the PPC and 84 in the placebo
group). A biochemical response (> 50% ALT reduction) was seen in 71% of patients
who were treated with PPC, but only in 56% of patients who received placebo (p <
0.05). PPC increased the response rate in particular in patients with hepatitis
C: 71% of those patients responded in the PPC group versus 51% in the placebo
group (p < 0.05). PROLONGED PPC THERAPY GIVEN TO RESPONDERS BEYOND THE CESSATION
OF INTERFERON THERAPY TENDED TO INCREASE THE RATE OF SUSTAINED RESPONDERS AT WEEK
48 IN PATIENTS WITH HEPATITIS C (41% VERSUS 15% IN THE CONTROL GROUP; p = 0.064).
In contrast, PPC did not alter the biochemical response to interferon in patients
with hepatitis B. PPC did not accelerate elimination of HBV-DNA, HBeAg and
HCV-RNA.
CONCLUSIONS:
In conclusion,
PPC may be recommended in patients with
chronic hepatitis C in combination with interferon and after termination of
interferon in order to reduce the high relapse rate.
6. THE DREADED "SOC"
(I also take 2000 mg of both salmon oil and flax oil along with Culturelle and Jarrow probiotics, 1 .5 tbl lactolose and 2 tsp inulan daily)
WELL, here I sit, started the Ribavirin this morning, NOT even ready or wanting to do this injection. Here's kinda how I'm feelin' 'bout now http://www.youtube.com/watch?v=03SmkMXR7MU It's 11.55 and I just dropped a 500/5 loratab (why go with tylenolPM when you squirreled back a couple of loras for a rainy day, heck it's POURING!!) Better go to the fridge and get the shot. signing off, jerry